• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CAMP4 Therapeutics Corporation

    10/16/24 4:07:08 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email
    S-8 1 tm2426234d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on October 16, 2024

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CAMP4 THERAPEUTICS CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

         
    Delaware   81-1152476

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    One Kendall Square

    Building 1400 West, 3rd Floor

    Cambridge, Massachusetts

      02139
    (Address of Principal Executive Offices)   (Zip Code)

     

    CAMP4 Therapeutics Corporation Amended and Restated 2016 Stock Option and Grant Plan

    CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan

    CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan

    (Full titles of the plans)

     

     

    Josh Mandel-Brehm

    Chief Executive Officer

    CAMP4 Therapeutics Corporation
    One Kendall Square, Building 1400 West, 3rd Floor

    Cambridge, Massachusetts 02139

    (Name and address of agent for service)

     

    (617) 651-8867

    (Telephone number, including area code, of agent for service)

     

     

    Please send a copy of all communications to:

    Thomas J. Danielski

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, Massachusetts 02199-3600

    617-951-7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by Rule 428(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants of the CAMP4 Therapeutics Corporation Amended and Restated 2016 Stock Option and Grant Plan, the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan and the CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan, as required by Rule 428(b). Such documents are not being filed with the Securities and Exchange Commission (the “SEC”) as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by CAMP4 Therapeutics Corporation (the “Registrant”) with the SEC are incorporated herein by reference:

     

    (a) the Registrant’s Current Report on Form 8-K filed with the SEC on October 15, 2024;
       
    (b) the Registrant’s prospectus filed with the SEC on October 11, 2024 pursuant to Rule 424(b) under the Securities Act relating to the registration statement on Form S-1 (File No. 333-282241), that contains audited financial statements of the Registrant for the latest fiscal period for which such statements have been filed; and
       
    (c) the description of the Registrant’s Common Stock, $0.0001 par value per share, which is contained in the Registrant’s registration statement on Form 8-A filed by the Registrant with the SEC under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on October 8, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated herein by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed report or document which also is incorporated or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    As permitted by Section 102(b)(7) of the General Corporation Law of the State of Delaware (the “DGCL”), our restated certificate of incorporation (our “Restated Charter”) includes a provision to eliminate the personal liability of our directors and officers for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, our Restated Charter and amended and restated bylaws provide that we are required to indemnify our officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and we are required to advance expenses to our officers and directors as incurred in connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors or officers for breaches of fiduciary duty.

     

    Section 145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful.

     

    Section 145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    We have entered into indemnification agreements with our directors and executive officers. These indemnification agreements provide broader indemnity rights than those provided under the DGCL and our Restated Charter. These indemnification agreements are not intended to deny or otherwise limit third-party or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a third-party suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement.

     

    We maintain directors’ and officers’ liability insurance for the benefit of our directors and officers.

     

     

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit    
       
    3.1   Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 15, 2024 and incorporated herein by reference).
       
    3.2   Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 15, 2024 and incorporated herein by reference).
         
    4.1   CAMP4 Therapeutics Corporation Amended and Restated 2016 Stock Option and Grant Plan, as amended, and form of award agreements thereunder (previously filed as Exhibit 10.4 to the registration statement on Form S-1 filed on September 20, 2024 (File No. 333-282241) and incorporated herein by reference).
         
    4.2*   CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan.
         
    4.3*   CAMP4 Therapeutics Corporation 2024 Employee Stock Purchase Plan.
         
    5.1*   Opinion of Ropes & Gray LLP.
         
    23.1*   Consent of Ernst & Young LLP.
         
    23.2*   Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1).
         
    24.1*   Powers of Attorney (included on the signature page in Part II).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
       
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
       
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
       
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Massachusetts, on this 16th day of October, 2024.

     

      CAMP4 THERAPEUTICS CORPORATION
         
      By: /s/ Josh Mandel-Brehm
        Name: Josh Mandel-Brehm
        Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Josh Mandel-Brehm and Kelly Gold, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by CAMP4 Therapeutics Corporation and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    * * * *

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Josh Mandel-Brehm   President, Chief Executive Officer and Director   October 16, 2024
    Josh Mandel-Brehm (Principal Executive Officer)  
             
    /s/ Kelly Gold   Chief Financial Officer   October 16, 2024
    Kelly Gold (Principal Financial Officer and Principal Accounting Officer)  
             
    /s/ Steven Holtzman   Director and Chair   October 16, 2024
    Steven Holtzman    
             
    /s/ James Boylan   Director   October 16, 2024
    James Boylan    
             
    /s/ Ingo Chakravarty   Director   October 16, 2024
    Ingo Chakravarty    
             
    /s/ Michael Higgins   Director   October 16, 2024
    Michael Higgins    
             
    /s/ Amir Nashat   Director   October 16, 2024
    Amir Nashat, ScD    
             
    /s/ Paula Ragan   Director   October 16, 2024
    Paula Ragan, PhD    
             
    /s/ Andrew J. Schwab   Director   October 16, 2024
    Andrew J. Schwab        
             
    /s/ Ravi I. Thadhani   Director   October 16, 2024
    Ravi I. Thadhani, MD, MPH    
             
    /s/ Richard Young   Director   October 16, 2024
    Richard Young, PhD        

     

     

     

    Get the next $CAMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    9/16/2025Overweight → Neutral
    Analyst
    5/27/2025$8.00Outperform
    Wedbush
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    More analyst ratings

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the C

    1/16/26 4:05:00 PM ET
    $CAMP

    CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST. The event will be webcast and can be accessed on the investor relations page of CAMP4's website at

    1/6/26 8:00:00 AM ET
    $CAMP

    CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of $6.00 per share. The gross proceeds to the Company from this offering are expected to be $30.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close

    12/18/25 7:10:00 AM ET
    $CAMP

    $CAMP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)

    2/5/26 1:20:38 PM ET
    $CAMP

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    1/9/26 4:32:35 PM ET
    $CAMP

    SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    1/8/26 12:15:25 PM ET
    $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    SEC Form 4 filed by Chief Scientific Officer Tardiff Daniel

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:42:07 PM ET
    $CAMP

    SEC Form 4 filed by Chief Medical Officer Maricich Yuri

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:49 PM ET
    $CAMP

    SEC Form 4 filed by Chief Financial Officer Gold Kelly

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:33 PM ET
    $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on CAMP4 Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00

    10/2/25 8:38:59 AM ET
    $CAMP

    CAMP4 Therapeutics downgraded by Analyst

    Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral

    9/16/25 8:02:50 AM ET
    $CAMP

    Wedbush initiated coverage on CAMP4 Therapeutics with a new price target

    Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/27/25 9:09:57 AM ET
    $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    View All

    Sequans Appoints Jason W. Cohenour to Board of Directors

    Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

    6/30/25 8:00:00 AM ET
    $CAMP
    $LTRX
    $RFIL
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

    With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

    3/18/25 8:00:00 AM ET
    $CAMP

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 6:49:57 PM ET
    $CAMP

    SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

    SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 5:50:56 PM ET
    $CAMP

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 4:19:08 PM ET
    $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    View All

    CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

    1/9/24 4:30:00 PM ET
    $CAMP

    CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

    12/26/23 4:30:00 PM ET
    $CAMP

    CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

    12/18/23 4:31:00 PM ET
    $CAMP